Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2017

View Archived Issues

DPLG-3 promotes long-term cardiac allograft acceptance in mice

Wnt-FZD5 signaling circuit is a druggable target for RNF43-mutant pancreatic tumors

MAVS signaling in myeloid cells is critical for resistance to Ebola in murine models of infection

Detailed NETTER-1 results published for 177Lu-Dotatate in midgut neuroendocrine cancer

PfSPZ Vaccine protects against controlled malaria infection

Sunesis Pharmaceuticals provides update on lead programs

Merck KGaA and Domain Therapeutics announce license and collaboration agreement

Positive preliminary phase II data from children with CDKL5 genetic disorder

ADMA Biologics enters agreement to acquire assets from Biotest Pharmaceuticals

Macrocure completes merger with Leap Therapeutics

Peptide vaccine OCV-C02 safe and well tolerated in metastatic colorectal cancer patients

GeoVax begins new study of HIV vaccine

European orphan drug designation for Therabron's CG-367 for bronchiolitis obliterans syndrome

Aptose prioritizes development of its first-in class FLT3/BTK inhibitor

ViiV Healthcare UK presents novel HIV integrase inhibitors

Shionogi describes new high affinity nerve growth factor receptor inhibtors

FDA clears NantKwest's IND for phase I trial of haNK cell therapy

First patient enrolled in phase IIb CaLIPSO study of SNF-472

Bayer Pharma describes coagulation factor XIa and kallikrein B inhibitors

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Enteris BioPharma, Sanofi enter diabetes collaboration

Roche, Genentech identify novel RIP-1 inhibitors

Crinetics Pharmaceuticals discloses novel somatostatin sst2 receptor agonists

Eagle Pharmaceuticals completes NDA submission for Ryanodex

Immune Pharmaceuticals enters antibody collaboration with SATT Sud-Est

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...